| 
																	
																	
																		 Laura Dunn
 
																		 Concepts  (488)
																		
																	 
																		Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months. 
																			
																					
    Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
     | Name | Number of Publications | Most Recent Publication | Publications by All Authors | Concept Score | Why? | 
|---|
 | Neoplasms | 49 | 2024 | 1325 | 5.510 | Why? |  | Informed Consent | 37 | 2017 | 95 | 5.430 | Why? |  | Decision Making | 31 | 2017 | 282 | 3.830 | Why? |  | Depression | 27 | 2024 | 600 | 2.600 | Why? |  | Mental Competency | 23 | 2017 | 32 | 2.550 | Why? |  | Breast Neoplasms | 31 | 2022 | 1212 | 2.500 | Why? |  | Biomedical Research | 14 | 2019 | 256 | 2.150 | Why? |  | Patient Participation | 7 | 2019 | 69 | 2.140 | Why? |  | Anxiety | 15 | 2024 | 300 | 2.100 | Why? |  | Adaptation, Psychological | 11 | 2024 | 230 | 2.050 | Why? |  | Fatigue | 23 | 2023 | 125 | 2.030 | Why? |  | Quality of Life | 28 | 2023 | 879 | 2.030 | Why? |  | Schizophrenia | 16 | 2008 | 254 | 1.940 | Why? |  | Research Subjects | 11 | 2019 | 52 | 1.830 | Why? |  | Patients | 5 | 2022 | 51 | 1.790 | Why? |  | Clinical Trials as Topic | 17 | 2023 | 467 | 1.740 | Why? |  | Third-Party Consent | 7 | 2013 | 16 | 1.740 | Why? |  | Middle Aged | 108 | 2024 | 13028 | 1.710 | Why? |  | Alzheimer Disease | 9 | 2025 | 332 | 1.630 | Why? |  | Clergy | 4 | 2017 | 25 | 1.590 | Why? |  | Female | 135 | 2025 | 28171 | 1.510 | Why? |  | Stress, Psychological | 13 | 2024 | 273 | 1.500 | Why? |  | Humans | 182 | 2025 | 52483 | 1.490 | Why? |  | Caregivers | 13 | 2021 | 240 | 1.480 | Why? |  | Schizophrenic Psychology | 12 | 2011 | 67 | 1.460 | Why? |  | Antineoplastic Agents | 15 | 2023 | 1222 | 1.460 | Why? |  | Ethics, Research | 7 | 2016 | 39 | 1.310 | Why? |  | Aged | 83 | 2025 | 10121 | 1.290 | Why? |  | Proxy | 4 | 2013 | 8 | 1.250 | Why? |  | Adult | 72 | 2024 | 14161 | 1.200 | Why? |  | Male | 103 | 2025 | 26761 | 1.200 | Why? |  | Depressive Disorder | 10 | 2023 | 334 | 1.170 | Why? |  | Mental Disorders | 8 | 2019 | 428 | 1.170 | Why? |  | Psychiatry | 6 | 2018 | 100 | 1.160 | Why? |  | Cognition Disorders | 11 | 2021 | 196 | 1.140 | Why? |  | Psychotic Disorders | 10 | 2018 | 139 | 1.110 | Why? |  | Needs Assessment | 4 | 2018 | 140 | 1.080 | Why? |  | Comprehension | 7 | 2016 | 113 | 1.060 | Why? |  | Psychotherapy | 6 | 2021 | 113 | 1.020 | Why? |  | Spiritual Therapies | 2 | 2017 | 6 | 1.000 | Why? |  | Patient Preference | 2 | 2016 | 43 | 1.000 | Why? |  | Cytokines | 10 | 2017 | 623 | 0.970 | Why? |  | Palliative Care | 4 | 2017 | 214 | 0.960 | Why? |  | Longitudinal Studies | 33 | 2024 | 747 | 0.950 | Why? |  | Dementia | 3 | 2017 | 134 | 0.940 | Why? |  | Personality | 2 | 2022 | 30 | 0.850 | Why? |  | Aged, 80 and over | 27 | 2025 | 3392 | 0.830 | Why? |  | Therapeutic Misconception | 4 | 2017 | 4 | 0.820 | Why? |  | Ambulatory Care | 8 | 2017 | 239 | 0.810 | Why? |  | Genetic Research | 2 | 2019 | 4 | 0.800 | Why? |  | Internship and Residency | 5 | 2011 | 448 | 0.800 | Why? |  | Mastectomy | 8 | 2021 | 143 | 0.790 | Why? |  | Psychiatric Status Rating Scales | 10 | 2017 | 323 | 0.740 | Why? |  | Deep Brain Stimulation | 4 | 2020 | 43 | 0.730 | Why? |  | Health Services Research | 5 | 2016 | 153 | 0.720 | Why? |  | Polymorphism, Single Nucleotide | 14 | 2017 | 505 | 0.710 | Why? |  | Severity of Illness Index | 23 | 2019 | 1026 | 0.700 | Why? |  | Radiotherapy | 3 | 2018 | 127 | 0.680 | Why? |  | Mental Health | 5 | 2016 | 240 | 0.670 | Why? |  | Geriatric Psychiatry | 3 | 2017 | 9 | 0.660 | Why? |  | Self Concept | 1 | 2020 | 61 | 0.650 | Why? |  | Patient Rights | 1 | 2019 | 2 | 0.640 | Why? |  | Chaplaincy Service, Hospital | 2 | 2015 | 2 | 0.600 | Why? |  | Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 178 | 0.600 | Why? |  | Anxiety Disorders | 6 | 2022 | 130 | 0.590 | Why? |  | Choroid Neoplasms | 1 | 2018 | 6 | 0.590 | Why? |  | Pastoral Care | 1 | 2018 | 5 | 0.580 | Why? |  | Cyclonic Storms | 1 | 2018 | 8 | 0.580 | Why? |  | Eye Enucleation | 1 | 2018 | 11 | 0.580 | Why? |  | Disasters | 1 | 2018 | 19 | 0.580 | Why? |  | Pain | 10 | 2023 | 362 | 0.570 | Why? |  | Comorbidity | 12 | 2021 | 625 | 0.550 | Why? |  | Resilience, Psychological | 4 | 2024 | 33 | 0.540 | Why? |  | Self Report | 13 | 2021 | 210 | 0.530 | Why? |  | Education | 2 | 2010 | 40 | 0.530 | Why? |  | Research Personnel | 6 | 2019 | 71 | 0.530 | Why? |  | Circadian Rhythm | 5 | 2016 | 91 | 0.520 | Why? |  | Outpatients | 9 | 2022 | 125 | 0.510 | Why? |  | Genetic Variation | 4 | 2014 | 230 | 0.510 | Why? |  | Syndrome | 6 | 2023 | 247 | 0.500 | Why? |  | Attitude of Health Personnel | 2 | 2011 | 360 | 0.490 | Why? |  | Interdisciplinary Studies | 1 | 2015 | 4 | 0.480 | Why? |  | Risk Assessment | 7 | 2014 | 1327 | 0.480 | Why? |  | Research | 3 | 2006 | 107 | 0.470 | Why? |  | Multimedia | 4 | 2021 | 7 | 0.470 | Why? |  | Cross-Sectional Studies | 12 | 2022 | 1678 | 0.470 | Why? |  | Aging | 5 | 2015 | 701 | 0.450 | Why? |  | Melanoma | 1 | 2018 | 288 | 0.450 | Why? |  | Mastodynia | 5 | 2016 | 6 | 0.450 | Why? |  | Internet | 3 | 2016 | 263 | 0.440 | Why? |  | Fear | 1 | 2014 | 82 | 0.440 | Why? |  | Survivors | 1 | 2014 | 120 | 0.430 | Why? |  | Patient Education as Topic | 4 | 2011 | 321 | 0.420 | Why? |  | Patient Care Team | 2 | 2015 | 272 | 0.410 | Why? |  | Chronic Pain | 3 | 2023 | 177 | 0.400 | Why? |  | Pilot Projects | 9 | 2022 | 721 | 0.400 | Why? |  | Health Knowledge, Attitudes, Practice | 3 | 2016 | 509 | 0.400 | Why? |  | Motivation | 2 | 2021 | 282 | 0.400 | Why? |  | Physician-Patient Relations | 3 | 2016 | 143 | 0.400 | Why? |  | Interleukin-6 | 5 | 2014 | 278 | 0.390 | Why? |  | Disclosure | 1 | 2012 | 41 | 0.380 | Why? |  | Symptom Assessment | 5 | 2018 | 32 | 0.380 | Why? |  | Prostatic Neoplasms | 5 | 2013 | 398 | 0.360 | Why? |  | Patient Selection | 6 | 2016 | 259 | 0.350 | Why? |  | Ethics Committees, Research | 3 | 2019 | 15 | 0.340 | Why? |  | Neoplasm Recurrence, Local | 1 | 2014 | 649 | 0.340 | Why? |  | Patient Acceptance of Health Care | 2 | 2016 | 358 | 0.340 | Why? |  | Risk Factors | 14 | 2022 | 3889 | 0.340 | Why? |  | Socioeconomic Factors | 5 | 2017 | 610 | 0.330 | Why? |  | Feasibility Studies | 6 | 2020 | 406 | 0.320 | Why? |  | Attitude | 3 | 2018 | 70 | 0.320 | Why? |  | Medical Oncology | 4 | 2021 | 104 | 0.310 | Why? |  | Attention | 4 | 2014 | 168 | 0.310 | Why? |  | Prevalence | 11 | 2020 | 1006 | 0.310 | Why? |  | Bacteremia | 2 | 2021 | 92 | 0.310 | Why? |  | Clinical Protocols | 2 | 2006 | 108 | 0.310 | Why? |  | Parents | 1 | 2012 | 335 | 0.310 | Why? |  | Gastrointestinal Neoplasms | 2 | 2021 | 42 | 0.310 | Why? |  | Cognition | 2 | 2020 | 331 | 0.300 | Why? |  | California | 9 | 2020 | 90 | 0.290 | Why? |  | Sleep | 4 | 2022 | 187 | 0.290 | Why? |  | Smoking Cessation | 1 | 2011 | 315 | 0.290 | Why? |  | Spirituality | 2 | 2018 | 31 | 0.280 | Why? |  | Age Factors | 12 | 2016 | 1132 | 0.280 | Why? |  | Neuropsychological Tests | 3 | 2012 | 338 | 0.270 | Why? |  | Burnout, Professional | 1 | 2008 | 55 | 0.270 | Why? |  | Wakefulness | 3 | 2012 | 49 | 0.270 | Why? |  | Aptitude | 1 | 2006 | 3 | 0.270 | Why? |  | Young Adult | 12 | 2020 | 4329 | 0.270 | Why? |  | Clinical Competence | 1 | 2010 | 406 | 0.260 | Why? |  | Emotions | 4 | 2021 | 174 | 0.260 | Why? |  | Life Change Events | 2 | 2017 | 36 | 0.250 | Why? |  | Genotype | 8 | 2015 | 566 | 0.250 | Why? |  | Factor Analysis, Statistical | 8 | 2017 | 86 | 0.250 | Why? |  | Staphylococcal Infections | 2 | 2021 | 285 | 0.250 | Why? |  | Placebos | 1 | 2005 | 85 | 0.240 | Why? |  | Randomized Controlled Trials as Topic | 5 | 2020 | 595 | 0.240 | Why? |  | Students, Medical | 1 | 2008 | 159 | 0.240 | Why? |  | Phenotype | 8 | 2016 | 789 | 0.240 | Why? |  | Tenosynovitis | 1 | 2005 | 5 | 0.240 | Why? |  | Health Promotion | 1 | 2008 | 270 | 0.240 | Why? |  | Tendons | 1 | 2005 | 26 | 0.240 | Why? |  | Foot | 1 | 2005 | 41 | 0.230 | Why? |  | Health Status | 5 | 2023 | 294 | 0.220 | Why? |  | Hospice Care | 3 | 2012 | 26 | 0.220 | Why? |  | Psychosocial Deprivation | 1 | 2003 | 2 | 0.210 | Why? |  | Random Allocation | 3 | 2017 | 285 | 0.210 | Why? |  | Head Injuries, Closed | 1 | 2003 | 7 | 0.210 | Why? |  | Interviews as Topic | 3 | 2013 | 275 | 0.210 | Why? |  | Cohort Studies | 5 | 2020 | 1542 | 0.210 | Why? |  | Anti-Bacterial Agents | 3 | 2021 | 807 | 0.210 | Why? |  | Prospective Studies | 10 | 2021 | 2481 | 0.210 | Why? |  | Carcinoma, Basal Cell | 1 | 2023 | 40 | 0.210 | Why? |  | Research Design | 6 | 2012 | 359 | 0.210 | Why? |  | Follow-Up Studies | 4 | 2018 | 2279 | 0.210 | Why? |  | Psychometrics | 5 | 2007 | 230 | 0.210 | Why? |  | Genetic Predisposition to Disease | 4 | 2014 | 528 | 0.200 | Why? |  | Genital Neoplasms, Female | 1 | 2023 | 48 | 0.200 | Why? |  | Pain, Postoperative | 2 | 2014 | 169 | 0.200 | Why? |  | United States | 14 | 2020 | 5192 | 0.200 | Why? |  | Promoter Regions, Genetic | 3 | 2013 | 467 | 0.200 | Why? |  | Reproducibility of Results | 5 | 2024 | 1229 | 0.190 | Why? |  | Career Choice | 1 | 2003 | 116 | 0.190 | Why? |  | Analysis of Variance | 5 | 2013 | 554 | 0.190 | Why? |  | Tumor Necrosis Factor-alpha | 3 | 2014 | 399 | 0.190 | Why? |  | Antibodies, Monoclonal, Humanized | 1 | 2023 | 236 | 0.190 | Why? |  | Antipsychotic Agents | 4 | 2006 | 235 | 0.190 | Why? |  | Psychotherapy, Brief | 1 | 2021 | 6 | 0.180 | Why? |  | Sick Role | 1 | 2001 | 13 | 0.180 | Why? |  | Chi-Square Distribution | 5 | 2015 | 288 | 0.180 | Why? |  | Vulnerable Populations | 2 | 2011 | 52 | 0.180 | Why? |  | Transcranial Magnetic Stimulation | 1 | 2021 | 72 | 0.180 | Why? |  | Mood Disorders | 1 | 2021 | 59 | 0.170 | Why? |  | Pregnancy Trimester, First | 1 | 2020 | 23 | 0.170 | Why? |  | Age Distribution | 4 | 2014 | 174 | 0.170 | Why? |  | Physical Endurance | 1 | 2020 | 34 | 0.170 | Why? |  | Qualitative Research | 2 | 2024 | 364 | 0.170 | Why? |  | Self Efficacy | 1 | 2001 | 134 | 0.170 | Why? |  | Social Support | 3 | 2015 | 268 | 0.170 | Why? |  | Antibodies, Neutralizing | 1 | 2020 | 78 | 0.170 | Why? |  | Antibodies, Viral | 1 | 2020 | 109 | 0.170 | Why? |  | Pandemics | 2 | 2025 | 585 | 0.170 | Why? |  | Algorithms | 1 | 2024 | 672 | 0.170 | Why? |  | Immunoglobulin G | 1 | 2020 | 195 | 0.160 | Why? |  | Population Surveillance | 1 | 2020 | 165 | 0.160 | Why? |  | Epigenesis, Genetic | 1 | 2023 | 406 | 0.160 | Why? |  | Physician's Role | 1 | 2019 | 49 | 0.160 | Why? |  | Constipation | 1 | 2019 | 37 | 0.160 | Why? |  | Employment | 1 | 2020 | 93 | 0.160 | Why? |  | Pregnancy Complications, Infectious | 1 | 2020 | 81 | 0.160 | Why? |  | Family | 4 | 2015 | 176 | 0.160 | Why? |  | Taste | 1 | 2019 | 30 | 0.160 | Why? |  | Breast | 2 | 2021 | 85 | 0.160 | Why? |  | Telemedicine | 1 | 2025 | 494 | 0.150 | Why? |  | Health Services Accessibility | 1 | 2003 | 436 | 0.150 | Why? |  | Genetics | 1 | 2018 | 5 | 0.150 | Why? |  | Diarrhea | 1 | 2019 | 95 | 0.150 | Why? |  | Truth Disclosure | 1 | 2018 | 16 | 0.150 | Why? |  | Amoxicillin-Potassium Clavulanate Combination | 1 | 2018 | 8 | 0.150 | Why? |  | Abdominal Pain | 1 | 2019 | 85 | 0.150 | Why? |  | Premenopause | 1 | 2018 | 27 | 0.150 | Why? |  | Specialties, Nursing | 1 | 1998 | 3 | 0.150 | Why? |  | Escherichia coli Infections | 1 | 2018 | 29 | 0.150 | Why? |  | Ruthenium Radioisotopes | 1 | 2018 | 1 | 0.150 | Why? |  | Professional Autonomy | 1 | 1998 | 7 | 0.150 | Why? |  | Tape Recording | 1 | 2018 | 7 | 0.150 | Why? |  | Skin Neoplasms | 1 | 2023 | 505 | 0.150 | Why? |  | Logistic Models | 4 | 2013 | 925 | 0.150 | Why? |  | New York City | 1 | 2018 | 25 | 0.150 | Why? |  | Proton Therapy | 1 | 2018 | 12 | 0.150 | Why? |  | Adolescent | 8 | 2020 | 6739 | 0.150 | Why? |  | Trust | 1 | 2018 | 63 | 0.150 | Why? |  | Career Mobility | 1 | 1998 | 29 | 0.150 | Why? |  | Cholinergic Agents | 1 | 2017 | 5 | 0.140 | Why? |  | Urinary Tract Infections | 1 | 2018 | 57 | 0.140 | Why? |  | Education, Nursing, Graduate | 1 | 1998 | 21 | 0.140 | Why? |  | Brachytherapy | 1 | 2018 | 48 | 0.140 | Why? |  | Lung Neoplasms | 2 | 2017 | 636 | 0.140 | Why? |  | Postmenopause | 1 | 2018 | 82 | 0.140 | Why? |  | Social Stigma | 1 | 2018 | 48 | 0.140 | Why? |  | Menopause | 1 | 2017 | 38 | 0.140 | Why? |  | Postoperative Period | 2 | 2014 | 170 | 0.140 | Why? |  | Actigraphy | 6 | 2012 | 23 | 0.140 | Why? |  | Pneumonia, Viral | 1 | 2020 | 178 | 0.140 | Why? |  | Antibodies | 1 | 2017 | 159 | 0.140 | Why? |  | Janus Kinases | 1 | 2017 | 7 | 0.140 | Why? |  | STAT Transcription Factors | 1 | 2017 | 8 | 0.140 | Why? |  | Skin Aging | 1 | 1997 | 12 | 0.140 | Why? |  | Coronavirus Infections | 1 | 2020 | 188 | 0.140 | Why? |  | Staphylococcus aureus | 2 | 2021 | 338 | 0.130 | Why? |  | Specialization | 1 | 2017 | 49 | 0.130 | Why? |  | Sex Characteristics | 3 | 2015 | 198 | 0.130 | Why? |  | Multivariate Analysis | 3 | 2013 | 591 | 0.130 | Why? |  | Certification | 1 | 2017 | 51 | 0.130 | Why? |  | Hand Strength | 1 | 2016 | 23 | 0.130 | Why? |  | Incidence | 3 | 2018 | 1062 | 0.130 | Why? |  | Upper Extremity | 1 | 2016 | 45 | 0.130 | Why? |  | Sex Distribution | 2 | 2014 | 137 | 0.130 | Why? |  | Depression, Postpartum | 1 | 2016 | 46 | 0.130 | Why? |  | Range of Motion, Articular | 1 | 2016 | 108 | 0.130 | Why? |  | Inflammasomes | 1 | 2017 | 66 | 0.130 | Why? |  | Primary Health Care | 1 | 2019 | 376 | 0.120 | Why? |  | Brain | 2 | 2020 | 1323 | 0.120 | Why? |  | Electronic Health Records | 1 | 2018 | 268 | 0.120 | Why? |  | Genome, Bacterial | 1 | 2015 | 58 | 0.120 | Why? |  | Survival Analysis | 1 | 2017 | 673 | 0.120 | Why? |  | Health Services Needs and Demand | 2 | 2014 | 159 | 0.120 | Why? |  | Drug Resistance, Multiple, Bacterial | 1 | 2015 | 70 | 0.120 | Why? |  | Pain Measurement | 5 | 2015 | 256 | 0.120 | Why? |  | Estrogens | 1 | 1997 | 223 | 0.120 | Why? |  | NF-kappa B | 1 | 2017 | 322 | 0.120 | Why? |  | Cluster Analysis | 3 | 2023 | 233 | 0.120 | Why? |  | Potassium Channels | 1 | 2015 | 32 | 0.120 | Why? |  | Risk | 2 | 2016 | 316 | 0.120 | Why? |  | Serotonin Agents | 1 | 2014 | 15 | 0.120 | Why? |  | Catecholamines | 1 | 2014 | 44 | 0.120 | Why? |  | Individuality | 3 | 2021 | 29 | 0.110 | Why? |  | Treatment Refusal | 2 | 2006 | 35 | 0.110 | Why? |  | Professional Role | 1 | 2015 | 78 | 0.110 | Why? |  | Tuberculosis | 1 | 2015 | 152 | 0.110 | Why? |  | gamma-Aminobutyric Acid | 1 | 2014 | 62 | 0.110 | Why? |  | Receptors, Interferon | 1 | 2014 | 4 | 0.110 | Why? |  | Time Factors | 7 | 2018 | 2968 | 0.110 | Why? |  | Terminal Care | 1 | 2015 | 48 | 0.110 | Why? |  | Lymph Node Excision | 3 | 2021 | 133 | 0.110 | Why? |  | Models, Statistical | 2 | 2012 | 230 | 0.110 | Why? |  | Sex Factors | 5 | 2020 | 727 | 0.110 | Why? |  | Data Collection | 3 | 2011 | 290 | 0.110 | Why? |  | Drug Therapy | 2 | 2006 | 44 | 0.110 | Why? |  | Receptors, Interleukin-1 Type I | 1 | 2013 | 2 | 0.110 | Why? |  | Educational Status | 3 | 2020 | 226 | 0.110 | Why? |  | Australia | 4 | 2015 | 89 | 0.110 | Why? |  | Home Care Services | 1 | 2015 | 72 | 0.110 | Why? |  | NF-kappa B p52 Subunit | 1 | 2013 | 6 | 0.110 | Why? |  | Mycobacterium tuberculosis | 1 | 2015 | 291 | 0.110 | Why? |  | Linear Models | 4 | 2020 | 287 | 0.100 | Why? |  | Cooperative Behavior | 1 | 2015 | 227 | 0.100 | Why? |  | Regression Analysis | 4 | 2015 | 401 | 0.100 | Why? |  | Guidelines as Topic | 2 | 2013 | 111 | 0.100 | Why? |  | Air | 1 | 2012 | 23 | 0.100 | Why? |  | Health Services, Indigenous | 1 | 2012 | 5 | 0.100 | Why? |  | Allied Health Occupations | 1 | 2012 | 9 | 0.100 | Why? |  | Delivery of Health Care | 3 | 2024 | 323 | 0.100 | Why? |  | Affect | 2 | 2023 | 104 | 0.100 | Why? |  | Activity Cycles | 1 | 2012 | 4 | 0.100 | Why? |  | Obesity | 1 | 2020 | 1162 | 0.100 | Why? |  | Chemotherapy, Adjuvant | 3 | 2017 | 124 | 0.100 | Why? |  | Genetic Association Studies | 4 | 2014 | 122 | 0.090 | Why? |  | Grief | 2 | 2021 | 10 | 0.090 | Why? |  | Radiometry | 1 | 2012 | 127 | 0.090 | Why? |  | Diagnostic Self Evaluation | 1 | 2011 | 14 | 0.090 | Why? |  | Quality Assurance, Health Care | 1 | 2012 | 149 | 0.090 | Why? |  | Treatment Failure | 1 | 2011 | 122 | 0.090 | Why? |  | Inflammation Mediators | 1 | 2012 | 115 | 0.090 | Why? |  | Disease Progression | 3 | 2023 | 871 | 0.090 | Why? |  | Preoperative Period | 3 | 2018 | 46 | 0.090 | Why? |  | Societies, Medical | 1 | 2012 | 200 | 0.090 | Why? |  | Postoperative Complications | 2 | 2016 | 1068 | 0.090 | Why? |  | Suicide | 2 | 2009 | 85 | 0.090 | Why? |  | Family Relations | 1 | 2011 | 23 | 0.090 | Why? |  | Gene Expression Profiling | 1 | 2016 | 1105 | 0.090 | Why? |  | Ethics, Medical | 1 | 2011 | 43 | 0.090 | Why? |  | Evidence-Based Practice | 1 | 2011 | 112 | 0.080 | Why? |  | Inpatients | 1 | 2011 | 205 | 0.080 | Why? |  | Drug Resistance, Bacterial | 2 | 2021 | 82 | 0.080 | Why? |  | Patient Satisfaction | 1 | 2011 | 284 | 0.080 | Why? |  | Knowledge | 2 | 2007 | 27 | 0.080 | Why? |  | England | 2 | 2020 | 58 | 0.080 | Why? |  | Case-Control Studies | 4 | 2017 | 1201 | 0.080 | Why? |  | Government Regulation | 1 | 2009 | 15 | 0.080 | Why? |  | Inflammation | 2 | 2012 | 641 | 0.080 | Why? |  | New Mexico | 1 | 2009 | 12 | 0.080 | Why? |  | Predictive Value of Tests | 3 | 2012 | 944 | 0.080 | Why? |  | Prejudice | 1 | 2009 | 37 | 0.080 | Why? |  | Terminally Ill | 1 | 2008 | 13 | 0.080 | Why? |  | Mental Health Services | 1 | 2011 | 212 | 0.070 | Why? |  | Attitude to Health | 1 | 2010 | 192 | 0.070 | Why? |  | Karnofsky Performance Status | 3 | 2012 | 9 | 0.070 | Why? |  | Demography | 2 | 2022 | 90 | 0.070 | Why? |  | Axilla | 2 | 2020 | 92 | 0.070 | Why? |  | Smoking | 1 | 2011 | 520 | 0.070 | Why? |  | Mentors | 1 | 2008 | 57 | 0.070 | Why? |  | Brain Neoplasms | 1 | 2011 | 291 | 0.070 | Why? |  | Mass Screening | 2 | 2007 | 357 | 0.070 | Why? |  | Reference Standards | 1 | 2006 | 54 | 0.070 | Why? |  | Canada | 2 | 2019 | 104 | 0.070 | Why? |  | Decision Support Techniques | 1 | 2007 | 70 | 0.060 | Why? |  | Problem Solving | 1 | 2006 | 42 | 0.060 | Why? |  | Statistics as Topic | 1 | 2006 | 87 | 0.060 | Why? |  | Prognosis | 3 | 2018 | 2099 | 0.060 | Why? |  | Human Experimentation | 1 | 2005 | 11 | 0.060 | Why? |  | Hallux Rigidus | 1 | 2005 | 1 | 0.060 | Why? |  | Bipolar Disorder | 1 | 2007 | 199 | 0.060 | Why? |  | Infant, Newborn | 1 | 2012 | 2867 | 0.060 | Why? |  | Exercise Therapy | 1 | 2005 | 100 | 0.060 | Why? |  | Haplotypes | 2 | 2014 | 92 | 0.050 | Why? |  | Sensitivity and Specificity | 3 | 2016 | 891 | 0.050 | Why? |  | Hedgehog Proteins | 1 | 2023 | 34 | 0.050 | Why? |  | Amides | 1 | 2023 | 37 | 0.050 | Why? |  | Scotland | 1 | 2003 | 9 | 0.050 | Why? |  | Abbreviated Injury Scale | 1 | 2003 | 6 | 0.050 | Why? |  | Pain Management | 1 | 2005 | 178 | 0.050 | Why? |  | Patient Care Planning | 1 | 2004 | 68 | 0.050 | Why? |  | Bioethical Issues | 1 | 2003 | 11 | 0.050 | Why? |  | Multiple Trauma | 1 | 2003 | 32 | 0.050 | Why? |  | Ligands | 1 | 2023 | 206 | 0.050 | Why? |  | Causality | 2 | 2014 | 53 | 0.050 | Why? |  | Personal Satisfaction | 1 | 2023 | 75 | 0.050 | Why? |  | Nuclear Reactors | 1 | 1982 | 2 | 0.050 | Why? |  | Accidents | 1 | 1982 | 21 | 0.050 | Why? |  | Papillomaviridae | 2 | 2001 | 105 | 0.050 | Why? |  | Neurosurgical Procedures | 1 | 2003 | 135 | 0.050 | Why? |  | Antigen Presentation | 1 | 2001 | 26 | 0.050 | Why? |  | Immune Tolerance | 1 | 2001 | 91 | 0.050 | Why? |  | Reference Values | 1 | 2002 | 313 | 0.050 | Why? |  | Treatment Outcome | 3 | 2018 | 5422 | 0.050 | Why? |  | Alleles | 2 | 2013 | 276 | 0.050 | Why? |  | Pregnancy | 2 | 2020 | 2680 | 0.050 | Why? |  | Polymorphism, Genetic | 2 | 2014 | 185 | 0.040 | Why? |  | Hospital Mortality | 1 | 2003 | 435 | 0.040 | Why? |  | Antigens, Neoplasm | 1 | 2001 | 147 | 0.040 | Why? |  | Nucleus Accumbens | 1 | 2020 | 27 | 0.040 | Why? |  | Survival Rate | 1 | 2003 | 945 | 0.040 | Why? |  | Seroepidemiologic Studies | 1 | 2020 | 44 | 0.040 | Why? |  | Genome-Wide Association Study | 1 | 2021 | 186 | 0.040 | Why? |  | Motor Activity | 2 | 2012 | 223 | 0.040 | Why? |  | Single-Blind Method | 1 | 2020 | 116 | 0.040 | Why? |  | Patient Compliance | 1 | 2002 | 230 | 0.040 | Why? |  | Interdisciplinary Communication | 2 | 2015 | 57 | 0.040 | Why? |  | Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 235 | 0.040 | Why? |  | Databases, Factual | 1 | 2003 | 706 | 0.040 | Why? |  | Religion | 1 | 2020 | 61 | 0.040 | Why? |  | Prenatal Diagnosis | 1 | 2020 | 103 | 0.040 | Why? |  | ROC Curve | 2 | 2012 | 253 | 0.040 | Why? |  | Mastectomy, Segmental | 1 | 2020 | 93 | 0.040 | Why? |  | Tumor Virus Infections | 1 | 1999 | 48 | 0.040 | Why? |  | Sentinel Lymph Node Biopsy | 1 | 2020 | 120 | 0.040 | Why? |  | Physicians, Family | 1 | 2019 | 65 | 0.040 | Why? |  | Diabetes Mellitus, Type 2 | 1 | 2005 | 560 | 0.040 | Why? |  | DNA Methylation | 1 | 2023 | 592 | 0.040 | Why? |  | Job Description | 1 | 1998 | 8 | 0.040 | Why? |  | Training Support | 1 | 1998 | 10 | 0.040 | Why? |  | Population Groups | 1 | 2018 | 7 | 0.040 | Why? |  | Professional Competence | 1 | 1998 | 42 | 0.040 | Why? |  | Morals | 1 | 2018 | 49 | 0.040 | Why? |  | Curriculum | 2 | 2011 | 398 | 0.040 | Why? |  | Drugs, Investigational | 1 | 2017 | 14 | 0.040 | Why? |  | School Admission Criteria | 1 | 1998 | 35 | 0.040 | Why? |  | Hypesthesia | 1 | 2017 | 16 | 0.040 | Why? |  | Nausea | 1 | 2017 | 46 | 0.030 | Why? |  | Amyloid | 1 | 2017 | 36 | 0.030 | Why? |  | Back Pain | 1 | 2017 | 39 | 0.030 | Why? |  | Papillomavirus Infections | 1 | 1999 | 173 | 0.030 | Why? |  | Consent Forms | 1 | 2016 | 6 | 0.030 | Why? |  | Mammaplasty | 1 | 2016 | 43 | 0.030 | Why? |  | Periodicity | 1 | 2016 | 26 | 0.030 | Why? |  | Neoplasm Metastasis | 1 | 2016 | 243 | 0.030 | Why? |  | Health Surveys | 1 | 1997 | 238 | 0.030 | Why? |  | Executive Function | 1 | 2016 | 72 | 0.030 | Why? |  | Immunotherapy | 1 | 2017 | 244 | 0.030 | Why? |  | Geriatric Assessment | 1 | 2016 | 117 | 0.030 | Why? |  | Veterans | 1 | 2002 | 583 | 0.030 | Why? |  | Fellowships and Scholarships | 1 | 2017 | 127 | 0.030 | Why? |  | Neoadjuvant Therapy | 1 | 2016 | 125 | 0.030 | Why? |  | Forecasting | 1 | 2015 | 154 | 0.030 | Why? |  | Signal Transduction | 1 | 2001 | 1671 | 0.030 | Why? |  | Microbial Sensitivity Tests | 1 | 2015 | 284 | 0.030 | Why? |  | Time | 1 | 2014 | 28 | 0.030 | Why? |  | Disability Evaluation | 1 | 2014 | 92 | 0.030 | Why? |  | Magnetic Resonance Imaging | 1 | 2001 | 1546 | 0.030 | Why? |  | Perception | 1 | 2015 | 120 | 0.030 | Why? |  | Genetic Testing | 1 | 2015 | 129 | 0.030 | Why? |  | Data Interpretation, Statistical | 1 | 2015 | 164 | 0.030 | Why? |  | National Institute of Mental Health (U.S.) | 1 | 2013 | 2 | 0.030 | Why? |  | Genetic Markers | 1 | 2014 | 109 | 0.030 | Why? |  | Focus Groups | 1 | 2015 | 196 | 0.030 | Why? |  | Homozygote | 1 | 2013 | 59 | 0.030 | Why? |  | Cancer Care Facilities | 1 | 2013 | 19 | 0.030 | Why? |  | Heterozygote | 1 | 2013 | 90 | 0.030 | Why? |  | Urination | 1 | 2013 | 20 | 0.030 | Why? |  | Watchful Waiting | 1 | 2013 | 28 | 0.030 | Why? |  | Sexuality | 1 | 2013 | 14 | 0.030 | Why? |  | Ambulatory Care Facilities | 1 | 2013 | 124 | 0.030 | Why? |  | Prostatectomy | 1 | 2013 | 84 | 0.030 | Why? |  | Luminescent Measurements | 1 | 2012 | 16 | 0.030 | Why? |  | Queensland | 1 | 2012 | 4 | 0.030 | Why? |  | Exercise | 1 | 2017 | 547 | 0.030 | Why? |  | San Francisco | 1 | 2012 | 13 | 0.030 | Why? |  | Disorders of Excessive Somnolence | 1 | 2012 | 7 | 0.020 | Why? |  | Sleep Stages | 1 | 2012 | 40 | 0.020 | Why? |  | Interleukin-18 Receptor alpha Subunit | 1 | 2012 | 1 | 0.020 | Why? |  | Interleukin-3 | 1 | 2012 | 12 | 0.020 | Why? |  | Monte Carlo Method | 1 | 2012 | 87 | 0.020 | Why? |  | Preoperative Care | 1 | 2013 | 173 | 0.020 | Why? |  | Women's Health | 1 | 2012 | 82 | 0.020 | Why? |  | Gene Expression Regulation, Neoplastic | 1 | 2016 | 857 | 0.020 | Why? |  | Interview, Psychological | 1 | 2011 | 23 | 0.020 | Why? |  | Models, Theoretical | 1 | 2012 | 185 | 0.020 | Why? |  | Odds Ratio | 1 | 2013 | 558 | 0.020 | Why? |  | Goals | 1 | 2011 | 43 | 0.020 | Why? |  | Rest | 1 | 2011 | 60 | 0.020 | Why? |  | Hospitalization | 2 | 2008 | 736 | 0.020 | Why? |  | Schools, Medical | 1 | 2011 | 69 | 0.020 | Why? |  | Polysomnography | 1 | 2010 | 73 | 0.020 | Why? |  | Papillomavirus E7 Proteins | 2 | 2001 | 32 | 0.020 | Why? |  | Models, Biological | 1 | 2013 | 735 | 0.020 | Why? |  | Cost of Illness | 1 | 2011 | 121 | 0.020 | Why? |  | Oncogene Proteins, Viral | 2 | 2001 | 54 | 0.020 | Why? |  | Gene Frequency | 1 | 2010 | 98 | 0.020 | Why? |  | Nursing Methodology Research | 1 | 2010 | 33 | 0.020 | Why? |  | Keratinocytes | 2 | 2001 | 93 | 0.020 | Why? |  | Clinical Nursing Research | 1 | 2009 | 10 | 0.020 | Why? |  | Electroencephalography | 1 | 2010 | 312 | 0.020 | Why? |  | Personality Disorders | 1 | 2008 | 22 | 0.020 | Why? |  | Federal Government | 1 | 2008 | 4 | 0.020 | Why? |  | Virginia | 1 | 2008 | 19 | 0.020 | Why? |  | Sleep Initiation and Maintenance Disorders | 1 | 2008 | 41 | 0.020 | Why? |  | Bioethics | 1 | 2007 | 15 | 0.020 | Why? |  | Matched-Pair Analysis | 1 | 2007 | 11 | 0.020 | Why? |  | Audiovisual Aids | 1 | 2007 | 13 | 0.020 | Why? |  | Quality of Health Care | 1 | 2008 | 187 | 0.020 | Why? |  | Reading | 1 | 2007 | 73 | 0.020 | Why? |  | Empiricism | 1 | 2005 | 1 | 0.020 | Why? |  | Chronic Disease | 1 | 2008 | 586 | 0.020 | Why? |  | Length of Stay | 1 | 2008 | 663 | 0.010 | Why? |  | Intelligence Tests | 1 | 2004 | 39 | 0.010 | Why? |  | Advisory Committees | 1 | 2003 | 71 | 0.010 | Why? |  | Pennsylvania | 1 | 1982 | 34 | 0.010 | Why? |  | Crisis Intervention | 1 | 1982 | 12 | 0.010 | Why? |  | Bereavement | 1 | 2002 | 13 | 0.010 | Why? |  | Probability | 1 | 2002 | 172 | 0.010 | Why? |  | Listeriosis | 1 | 2001 | 7 | 0.010 | Why? |  | Antigens, Bacterial | 1 | 2001 | 54 | 0.010 | Why? |  | Injections, Intravenous | 1 | 2001 | 138 | 0.010 | Why? |  | Skin Transplantation | 1 | 2001 | 44 | 0.010 | Why? |  | Tumor Cells, Cultured | 1 | 2001 | 460 | 0.010 | Why? |  | Graft Rejection | 1 | 2001 | 177 | 0.010 | Why? |  | Mice, Transgenic | 1 | 2001 | 552 | 0.010 | Why? |  | Interferon-alpha | 1 | 1999 | 53 | 0.010 | Why? |  | T-Lymphocytes, Cytotoxic | 1 | 1999 | 66 | 0.010 | Why? |  | Cells, Cultured | 1 | 2001 | 1567 | 0.010 | Why? |  | Viral Proteins | 1 | 1999 | 164 | 0.010 | Why? |  | Epithelial Cells | 1 | 1999 | 215 | 0.010 | Why? |  | Hematopoietic Stem Cells | 1 | 1999 | 187 | 0.010 | Why? |  | Mice, Inbred C57BL | 1 | 2001 | 1884 | 0.010 | Why? |  | Retrospective Studies | 1 | 2008 | 6607 | 0.010 | Why? |  | Animals | 2 | 2001 | 13505 | 0.010 | Why? |  | Mice | 1 | 2001 | 5949 | 0.010 | Why? | 
 | 
																	
																		
																			
																					
    Dunn's Networks
 
Click the "See All" links for more information and interactive visualizations!
 Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH._ Co-Authors  People in Profiles who have published with this person._ Similar People  People who share similar concepts with this person._ 
            
                Same Department   
				People who are also in this person's primary department.
			 |